Bunge Global SA
Slimming Down A Fat Share Price
Download Report
Bunge Global SA
Download Report 2
Bunge Global SA
Download Report 3
Bunge Global SA
Download Report 4
Bunge Global SA
Download Report 5
Bunge Global SA
Download Report 6
Bunge Global SA
Download Report 7

Research Overview

INDEX:
S&P 500
Sector:
Consumer Staples
Position:
Short
Date:
Mar 25, 2026

After conducting a forensic review of Bunge Global SA (NYSE: BG) (“Bunge” or the “Company”), an S&P 500 component and global agribusiness, Spruce Point calls for an independent investigation into the accuracy of its financial reporting and accounting. In our opinion, Bunge is a complex and troubled roll-up that has demonstrated an inability to deliver value to shareholders absent external financing. We provide evidence that since 1999, the Company has generated a cash flow deficit of -$1.6bn after capital expenditures, business investment, and asset-shuffling and repositioning, while making +$4.7bn and +$3.9bn of dividends and share repurchases effectively through debt-financing.

Our belief is that Bunge is under core pressure in oilseeds, once its highest EBIT contributor and which it once claimed was a global leading business and difficult to replicate. Bunge also says nothing about the growing impact of GLP-1 weight loss drugs in its SEC filings or conference calls, but with customers in the food products industry, we believe it is likely feeling the effects. Based on our evaluation, we estimate 55% - 80% potential downside and material market underperformance risk.

The report highlights several key concerns with the Company, including:

• In our opinion, Bunge is a complex and troubled roll-up facing growing core challenges that has demonstrated an inability to deliver value to shareholders absent external financing.

• Given mounting financial pressures, we view Bunge’s $10.6bn Viterra acquisition from Glencore (LSE: GLEN) announced in June 2023 as a deal borne out of necessity to deflect from its core challenges and a transaction, and we believe that it has wildly disappointed.

• Bunge claims to be committed to transparency so we believe the Board should investigate the following matters and provide more clarity around its financial reporting.

• Bunge’s share price is a poor risk / reward, new 2030 EPS guidance should be discounted, and extreme insider selling of up to 30% of the stock may be on the near-term horizon.

Downloads & More

Research Assets & Releases

Join The Mailing List

Spruce Point Alerts & Updates

See the other side of the Wall Street hype machine.